S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Financial Day of Reckoning Has Begun (Ad)
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
The Financial Day of Reckoning Has Begun (Ad)
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Financial Day of Reckoning Has Begun (Ad)
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
The Financial Day of Reckoning Has Begun (Ad)
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Financial Day of Reckoning Has Begun (Ad)
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
The Financial Day of Reckoning Has Begun (Ad)
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Financial Day of Reckoning Has Begun (Ad)
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
The Financial Day of Reckoning Has Begun (Ad)
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
NASDAQ:ABEO

Abeona Therapeutics - ABEO Stock Forecast, Price & News

$4.43
-0.23 (-4.94%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.38
$4.99
50-Day Range
$3.80
$5.56
52-Week Range
$3.26
$34.00
Volume
340,110 shs
Average Volume
266,859 shs
Market Capitalization
$26.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.00

Abeona Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
1,006.1% Upside
$49.00 Price Target
Short Interest
Healthy
3.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.03
Upright™ Environmental Score
News Sentiment
0.63mentions of Abeona Therapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$5,600 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.50) to ($2.54) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

312th out of 1,135 stocks

Pharmaceutical Preparations Industry

157th out of 557 stocks

ABEO stock logo

About Abeona Therapeutics (NASDAQ:ABEO) Stock

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Analysts Set New Price Targets

ABEO has been the subject of a number of recent analyst reports. Cantor Fitzgerald increased their price target on shares of Abeona Therapeutics from $15.00 to $22.00 in a research note on Thursday. StockNews.com began coverage on shares of Abeona Therapeutics in a research note on Friday, July 8th. They set a "sell" rating for the company.

Abeona Therapeutics Trading Down 4.9 %

Shares of Abeona Therapeutics stock opened at $4.43 on Friday. Abeona Therapeutics has a twelve month low of $3.26 and a twelve month high of $34.00. The company has a 50-day simple moving average of $4.41 and a two-hundred day simple moving average of $5.50.

Abeona Therapeutics (NASDAQ:ABEO - Get Rating) last issued its quarterly earnings data on Friday, May 13th. The biopharmaceutical company reported ($2.50) earnings per share for the quarter, missing the consensus estimate of ($2.00) by ($0.50). The business had revenue of $0.35 million for the quarter. Analysts predict that Abeona Therapeutics will post -3.5 EPS for the current fiscal year.

Receive ABEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ABEO Stock News Headlines

Abeona Therapeutics (NASDAQ:ABEO) Price Target Raised to $22.00
Abeona Therapeutics GAAP EPS of -$2.08, revenue of $1M
Recap: Abeona Therapeutics Q2 Earnings
Abeona Therapeutics Inc. (ABEO)
See More Headlines
Receive ABEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ABEO Company Calendar

Last Earnings
11/15/2021
Today
8/14/2022
Next Earnings (Estimated)
11/21/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABEO
Previous Symbol
OTCMKTS:ACCP
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$49.00
High Stock Price Forecast
$100.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+1,006.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-84,940,000.00
Pretax Margin
-2,681.56%

Debt

Sales & Book Value

Annual Sales
$3 million
Book Value
$8.73 per share

Miscellaneous

Free Float
5,733,000
Market Cap
$26.00 million
Optionable
Optionable
Beta
1.06

Key Executives

  • Mr. Steven H. Rouhandeh (Age 61)
    Exec. Chairman
  • Dr. Timothy J. Miller (Age 46)
    Pres, Chief Scientific Officer & Director
  • Mr. Jeffrey Blaine Davis (Age 55)
    Chief Operating Officer
  • Mr. Carsten Thiel (Age 54)
    Chief Exec. Officer
  • Mr. Stephen B. Thompson (Age 64)
    Sr. VP of Fin. and Admin., Chief Accounting Officer, Sec. & Treasurer













ABEO Stock - Frequently Asked Questions

Should I buy or sell Abeona Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abeona Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ABEO shares.
View ABEO analyst ratings
or view top-rated stocks.

What is Abeona Therapeutics' stock price forecast for 2022?

3 analysts have issued 12 month price objectives for Abeona Therapeutics' shares. Their ABEO share price forecasts range from $22.00 to $100.00. On average, they anticipate the company's share price to reach $49.00 in the next year. This suggests a possible upside of 1,006.1% from the stock's current price.
View analysts price targets for ABEO
or view top-rated stocks among Wall Street analysts.

How have ABEO shares performed in 2022?

Abeona Therapeutics' stock was trading at $8.4250 at the beginning of the year. Since then, ABEO stock has decreased by 47.4% and is now trading at $4.43.
View the best growth stocks for 2022 here
.

When is Abeona Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our ABEO earnings forecast
.

How were Abeona Therapeutics' earnings last quarter?

Abeona Therapeutics Inc (NASDAQ:ABEO) issued its quarterly earnings data on Monday, November, 15th. The biopharmaceutical company reported ($4.00) earnings per share for the quarter, hitting analysts' consensus estimates of ($4.00).

When did Abeona Therapeutics' stock split?

Abeona Therapeutics shares reverse split on the morning of Tuesday, July 5th 2022. The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Abeona Therapeutics own?

What is Abeona Therapeutics' stock symbol?

Abeona Therapeutics trades on the NASDAQ under the ticker symbol "ABEO."

Who are Abeona Therapeutics' major shareholders?

Abeona Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (40.83%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Brendan M O'malley, Edward Carr, Mark Alvino, Michael Amoroso, Paul Elliot Mann, Sco Capital Partners Llc, Stefano Buono and Todd Wider.
View institutional ownership trends
.

How do I buy shares of Abeona Therapeutics?

Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Abeona Therapeutics' stock price today?

One share of ABEO stock can currently be purchased for approximately $4.43.

How much money does Abeona Therapeutics make?

Abeona Therapeutics (NASDAQ:ABEO) has a market capitalization of $26.00 million and generates $3 million in revenue each year. The biopharmaceutical company earns $-84,940,000.00 in net income (profit) each year or ($18.58) on an earnings per share basis.

How can I contact Abeona Therapeutics?

Abeona Therapeutics' mailing address is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. The official website for the company is www.abeonatherapeutics.com. The biopharmaceutical company can be reached via phone at 214-665-9495, via email at ir@abeonatherapeutics.com, or via fax at 214-905-5101.

This page (NASDAQ:ABEO) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.